BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22529231)

  • 1. Cardiovascular primary prevention: how high should we set the bar?
    Prasad V; Vandross A
    Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [How far the rates of cholesterol have to be lowered in primary prevention?].
    Rodondi N
    Rev Med Suisse; 2010 Mar; 6(239):483-4. PubMed ID: 20373693
    [No Abstract]   [Full Text] [Related]  

  • 3. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 4. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 5. In brief: Zetia and Vytorin: the ENHANCE study.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
    [No Abstract]   [Full Text] [Related]  

  • 6. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence.
    Mascitelli L; Pezzetta F; Goldstein MR
    Arch Med Res; 2010 Nov; 41(8):649-50. PubMed ID: 21199735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and all-cause mortality in high-risk primary prevention: a second look at the results.
    Chodick G; Shalev V
    Arch Intern Med; 2010 Dec; 170(22):2041-2; author reply 2043-4. PubMed ID: 21149767
    [No Abstract]   [Full Text] [Related]  

  • 11. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating economic analysis into clinical trials.
    Imai K; Zhang P
    Lancet; 2005 May 21-27; 365(9473):1749-50. PubMed ID: 15910936
    [No Abstract]   [Full Text] [Related]  

  • 14. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
    Westerink J; Visseren FL
    Eur J Clin Invest; 2010 Jan; 40(1):87. PubMed ID: 19912317
    [No Abstract]   [Full Text] [Related]  

  • 15. [On the current debate on lowering LDL cholesterol with ezetimibe].
    Breuer HW
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008
    [No Abstract]   [Full Text] [Related]  

  • 16. [SBU should investigate what is an evidence-based and cost-effective use of statins].
    Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
    Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).
    Samson RH; Nair DG
    Semin Vasc Surg; 2011 Sep; 24(3):172-9. PubMed ID: 22153029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin.
    Olsson AG
    Nutr Metab Cardiovasc Dis; 2010 Oct; 20(8):553-7. PubMed ID: 20739153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.